Is immunotherapy here to stay in multiple myeloma?

Haematologica · 2017 · PMC5394971 · PMID 28082344

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

40 The most recently presented results showed a highly significant superiority for the experimental arm in terms of ORR (93% vs . 76%), CR rate (43% vs . 19%), TNT (not reached (NR) vs . 18.4 months), and PFS (NR vs . 18.4 months, HR 0.37 [0.27–0.52], P <0.0001), with an unprecedented estimated median PFS for the triplet DRd arm of 44 months in relapsed MM.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.